Novo Nordisk's Wegovy Pill Is Winning the Volume Battle. The 2027 Price Cut Is the War
Published on 11/04/2026 at 22:21 | Editorial boerse-global.de
Novo Nordisk has spent the past year proving its oral Wegovy can sell. The harder question, and the one its third-quarter 2026 report actually poses, is whether it can still pay once US list prices come down.
From 1 January 2027, the Danish drugmaker plans to cut the US list price of Wegovy by roughly 50% and Ozempic by about 35%, to $675 per month each. Management has already flagged that the move will weigh on cash flow next year. That single sentence reframes everything in the quarter: a product launch that looks like a triumph on volume has to be judged on what it leaves behind in operating profit and free cash.
The number that matters is not the pill
Strip out the headline and the most revealing figure is the combined US Wegovy business. Sales of the injectable form fell 13% in the third quarter at constant currencies, according to Reuters. Add the tablet and the total US Wegovy franchise grew 21%.
That gap is the whole investment case in miniature. The pill has more than offset the erosion of the shot, which is a real signal about its role in the franchise. It is not proof that extra volume will carry enough margin under the planned prices. Prescription records alone cannot settle that.
The tablet brought in DKK 5.39bn for the quarter, against a Reuters-cited analyst consensus of DKK 4.62bn — a 53% jump on the prior quarter. Obesity revenue across the division rose 22% at constant currencies to DKK 26.15bn, so the impulse reached the segment level, not just one product line.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A beat with a price-mix caveat
Operating leverage improved sharply. Adjusted operating profit hit DKK 31.72bn, up 27% at constant currencies, and Novo still guides to full-year free cash flow of DKK 60–70bn.
Jefferies, though, has picked apart the quality of that beat. A DKK 2bn gross-to-net pricing benefit flattered the quarter; without it, injectable Wegovy would have missed revenue expectations. That distinction matters for anyone extrapolating the print forward. The broker keeps a Hold rating and a DKK 275 target — credit for clearing the bar, but no blank cheque on valuation.
HSBC reaches a similar place from a different direction. The bank calls the quarter clearly better than expected but points to cautious full-year planning, which it calculates implies an 8% decline in fourth-quarter adjusted operating profit at constant currencies.
Where the bull case actually rests
The strongest argument for the pill is that it is not simply cannibalising shots. According to BioSpace's report on the results, 80% of patients who started on oral Wegovy had no prior treatment. If that holds, the tablet opens a genuinely wider demand base rather than reshuffling existing prescriptions — the difference between a new growth path and a swap.
Management, however, has acknowledged that pill prescriptions flattened recently on seasonal patterns. Citi's read on the four-week average of weekly prescriptions through 23 October showed them essentially unchanged. A pause is not a stall, but it does cap how much weight the quarter's momentum can bear.
Layer on the geographic split and the picture gets more nuanced still. Reuters notes that Novo's annual guidance assumes international revenue growth alongside a US decline — the company is not modelling a uniform recovery.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Two dates on the calendar
The first is 1 January 2027, when the US list-price cuts take effect. The second is the expected FDA decision on CagriSema before the end of 2026, with Novo planning a US launch in early 2027 subject to a positive verdict. Approval would widen the product base; it would not pre-empt the commercial verdict on the drug itself.
Worth remembering throughout: list prices are not realised prices, so the announced cuts do not translate one-for-one into revenue loss. The cash-flow warning, though, makes the topic immediately relevant to valuation.
What the quarter delivers is a better starting position, not a stress test. The test comes when volume growth has to hold up against lower revenue per treatment — and when the combined US Wegovy franchise, not the tablet alone, shows whether Novo can convert demand into durable earnings.
Ad
Novo Nordisk Stock: New Analysis - 4 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
